Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Margaret A. Lindorfer, Adrian Wiestner, Clive S. Zent, Ronald P. Taylor

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.

Original languageEnglish (US)
Pages (from-to)959-961
Number of pages3
Issue number6
StatePublished - 2012


  • CD20 mAbs
  • Immunomonitoring
  • Therapeutic antibodies
  • Therapeutic trials
  • Trogocytosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?'. Together they form a unique fingerprint.

Cite this